$CBIS Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV

Dr. Gary Blick will join the Cannabis Science Scientific Advisory Board adding his expertise in HIV to a list of members including Dr. Roscoe Moore, former US Assistant Surgeon General, and Mark Wainberg, Ph.D., Director of the McGill University AIDS Centre at the Montreal Jewish General Hospital and Professor of Medicine and of Microbiology at McGill University, along with several other noted and successful FDA drug developers.

Last week at the IAS 2015 ( www.ias2015.org ) conference in Vancouver, approaches to HIV TAT inhibition were extensively discussed by a global audience of scientists and clinicians. Currently, CBIS is the only commercial entity pursuing development of an HIV TAT inhibitor and is currently collaborating with leading investigators at multiple academic institutions.

“Dr. Blick will enhance the Company’s CS-TATI-1 development program with his extensive background in HIV clinical research. Cannabis Science is impressed by Dr. Blick’s commitment to people living with HIV and his outstanding history of dedication to advancing treatment of AIDS for the majority of the pandemic. We welcome him to our Scientific Advisory Board and look forward with anticipation to assisting Cannabis Science accomplish the necessary steps towards regulatory submission,” stated Chad S. Johnson, Esq., Director, COO & General Counsel, Cannabis Science Inc.

Dr. Gary Blick has over 30 years of experience as an HIV provider and has cared for more than 3,500 patients living with HIV. He is the Medical & Research Director of Circle Care Center and has been the Principal Investigator for over 110 clinical research trials. Dr. Blick has authored/co-authored more than 155 medical manuscripts and scientific presentations in the field of HIV. His work has been published in the Journal of Infectious Diseases (JID), Journal of AIDS (JAIDS), AIDS, Clinical Infectious Diseases, Journal of the American Medical Association (JAMA), Lancet, and many other renowned peer-reviewed medical journals.

“The global HIV antiretroviral market is currently valued at $15.5 Billion per annum. The prospects of a HIV TAT Inhibition has been examined by more than 2,000 academic papers as a predictive means of addressing HIV drug resistance. The HIV TAT protein is essential for the virus to reproduce and is related to the activation of KSHV and HIV related cancer and continues to present high rates of mortality for patients globally. We look forward to addressing this concern with our CS-TATI-1 drug development program,” concludes Mr. Raymond C. Dabney, President & CEO Cannabis Science Inc.

About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.